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OBJECTIVE—Insulin stimulates brain glucose metabolism, but
this effect of insulin is already maximal at fasting concentrations
in healthy subjects. It is not known whether insulin is able to
stimulate glucose metabolism above fasting concentrations in
patients with impaired glucose tolerance.
RESEARCH DESIGN AND METHODS—We studied the
effects of insulin on brain glucose metabolism and cerebral
blood ﬂow in 13 patients with impaired glucose tolerance and
nine healthy subjects using positron emission tomography (PET).
All subjects underwent PET with both [
18F]ﬂuorodeoxyglucose
(for brain glucose metabolism) and [
15O]H2O (for cerebral blood
ﬂow) in two separate conditions (in the fasting state and during
a euglycemic-hyperinsulinemic clamp). Arterial blood samples
were acquired during the PET scans to allow fully quantitative
modeling.
RESULTS—The hyperinsulinemic clamp increased brain glu-
cose metabolism only in patients with impaired glucose tolerance
(whole brain: +18%, P = 0.001) but not in healthy subjects (whole
brain: +3.9%, P = 0.373). The hyperinsulinemic clamp did not alter
cerebral blood ﬂow in either group.
CONCLUSIONS—We found that insulin stimulates brain glu-
cose metabolism at physiological postprandial levels in patients
with impaired glucose tolerance but not in healthy subjects.
These results suggest that insulin stimulation of brain glucose
metabolism is maximal at fasting concentrations in healthy
subjects but not in patients with impaired glucose tolerance.
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P
eripheral insulin resistance is a hallmark of met-
abolic syndrome and type 2 diabetes, but it is
unclear if the brain also shows insulin resistance.
Peripheral insulin crosses the blood-brain barrier
via an active transport mechanism and binds to insulin
receptors on neurons and glial cells. Insulin has a catabolic
effect; in addition, it inﬂuences memory functions by
modulating neurotransmitter release and synaptic plasticity
(1–4). Therefore, determining whether insulin resistance
also occurs in the brain in metabolic syndrome is im-
portant (5). Obese individuals have a decreased cere-
brospinal ﬂuid–to–plasma insulin ratio (6), diminished
catabolic responses to intranasal insulin (7), and de-
creased cortical brain activity after insulin (8), sug-
gesting brain insulin resistance (1,5). However, these
indirect studies do not establish the relationship between
insulin and brain glucose metabolism, which is important
given the role of the brain in glucose sensing (9).
Direct evidence on the effects of insulin on the brain
may be obtained with positron emission tomography (PET)
and
18F-labeled ﬂuorodeoxyglucose ([
18F]FDG). Studies
in healthy subjects have shown that brain glucose me-
tabolism does not increase after increasing plasma insulin
concentrations above physiological fasting levels (10,11)
but decreases after decreasing plasma insulin concen-
tration below physiological fasting levels (12,13), sug-
gesting that the insulin effect is already saturated at
fasting concentrations in healthy subjects. In contrast,
Anthony et al. (12) recently demonstrated that reducing
plasma insulin does not reduce brain glucose metabolism
in patients with impaired glucose tolerance. However, it
is not known whether insulin stimulates brain glucose
metabolism above fasting levels in these patients or
whether this effect is already saturated at fasting levels,
as in healthy subjects (12,13).
To characterize the dose-response relationship of
plasma insulin and brain glucose metabolism in patients
with impaired glucose tolerance, we used [
18F]FDG PET to
measure brain glucose metabolism in two conditions (in
the fasting state and during a euglycemic-hyperinsulinemic
clamp) in both healthy subjects and patients with impaired
glucose tolerance. [18F]FDG is a glucose analog that is
taken up in the brain and trapped after phosphorylation;
thus, the measured signal approximates uptake of glucose.
The euglycemic-hyperinsulinemic clamp allows close mon-
itoring and adjustment of plasma glucose while inducing
a constant insulin stimulation. In a subset of subjects, we
also measured the effects of insulin on cerebral blood ﬂow
with [
15O]H2O PET.
RESEARCH DESIGN AND METHODS
Twenty-two subjects (Table 1), classiﬁed either as healthy or as having im-
paired glucose tolerance (14), were recruited to participate in two PET studies
performed during the fasting state and euglycemic-hyperinsulinemia in sepa-
rate days in randomized order. The PET studies measured brain glucose me-
tabolism with [
18F]FDG (13 patients, nine healthy) and blood ﬂow with [
15O]
H2O (six patients, eight healthy). All subjects were not studied with [
15O]H2O
because this scan was omitted from the study based on interim results. All
subjects gave their written informed consent after the study had been approved
by the ethics committee of the hospital district of southwestern Finland.
Euglycemic-hyperinsulinemic clamp.The euglycemic-hyperinsulinemic clamp
(1 mU $ kg
21 $ min
21) technique was used during the PET scan, as previously
described (15,16).
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BRIEF REPORTPET acquisition. The PET studies were performed after a 12-h fast using the
General Electric Advance PET camera (General Electric Medical Systems,
Milwaukee, WI) (16). The [
15O]H2O PET scan started at 45 min and the [
18F]
FDG scan at 60 min after the position to the scanner or the start of euglycemic-
hyperinsulinemic clamp. The synthesis (17,18) and image acquisition (16,19)
of [
15O]H2O and [
18F]FDG were performed as previously described.
Quantiﬁcation of brain glucose metabolism. Glucose metabolism (CMRglu;
mmol $ 100 g
21 $ min
21) was calculated for each voxel separately using the
linear Gjedde-Patlak plot with the arterial plasma input function (linear start
time 10 min) as previously described (20). CMRglu images were normalized
into standard space as previously described (21) using SPM5 (www.ﬁl.ion.ucl.
ac.uk/spm/) running on Matlab for Windows (version 7.3.0.267; Math Works,
Natick, MA). Regions of interest (frontal cortex, temporal cortex, parietal
cortex, occipital cortex, mesial temporal cortex, insula, striatum, cerebellum,
and thalamus) were applied in standard space using Imadeus software (ver-
sion 1.2.; Forima, Turku, Finland) to obtain glucose metabolism values. Hy-
pothalamus was not included because it is too small to be reliably quantiﬁed.
Quantiﬁcation of cerebral blood ﬂow. Cerebral blood ﬂow (mL $ 100 g
21 $
min
21) was calculated for each voxel separately based on a one-tissue com-
partmental model using the arterial radioactivity concentration as the input
function as previously described (19). Image analysis for cerebral blood
images was done as described above for images of glucose metabolism.
Voxel-based mapping analysis. Voxel-based mapping analysis was done
using SPM5. Spatially normalized glucose metabolism images were smoothed
with 12-mm full width at half-maximum Gaussian kernel. Voxel maps of clamp
effects were created by subtracting fasting images from clamp images. These
subtraction images were compared between groups using T-contrasts, with and
without age as covariate, with voxel-level uncorrected P , 0.05 and cluster-
level corrected P , 0.05.
Statistical analyses of volume of interest data. Statistical analyses of
volume-of-interest data were done using SPSS version 17.0 for Windows (SPSS,
Chicago, IL). Data were analyzed using repeated-measures ANOVA with region,
hemisphere, and condition as within-subject factors; group status as the
between-subjectfactor;andsexasacovariate.Wealsoranthesamemodelwith
age as a covariate. We also used paired t tests within groups and independent-
samples t tests between groups. Data are mean 6 SD.
RESULTS
Brain glucose metabolism. In the fasting condition, brain
glucose metabolism was similar between patients with
impaired glucose metabolism (whole brain: 15.6 mmol $
100 g
21 $ min
21) and healthy subjects (whole brain: 15.0
mmol $ 100 g
21 $ min
21; +0.5%, P = 0.896).
Across all subjects, the hyperinsulinemic clamp in-
creased whole-brain glucose metabolism by ~12% (main
effect of the condition: F = 7.11, P = 0.015). However,
groups were different in terms of the treatment effects
(group 3 condition interaction: F = 8.59, P = 0.009). The
hyperinsulinemic clamp increased brain glucose metabo-
lism only in patients with impaired glucose tolerance
(whole brain: +18%, P = 0.001) but not in healthy subjects
(whole brain: +3.9%, P = 0.373) (Fig. 1; Table 2). This
ﬁnding was conﬁrmed by the voxel-based mapping analysis,
which showed a large signiﬁcant cluster throughout the
brain, with the largest increase in glucose metabolism in the
right posterior insula (Fig. 2). Although plasma insulin was
higher in patients than in healthy subjects, fasting (r =0 . 3 5 ,
P = 0.114) or clamp (r =0 . 0 5 ,P =0 . 8 4 2 )i n s u l i n ,o rt h e
change from fasting to clamp (r = 20.06, P = 0.792) insulin,
did not correlate with change in brain glucose metabolism.
Because the patients with impaired glucose tolerance
tended to be somewhat older than healthy subjects (Table 1),
we repeated the overall analysis with age as a covariate.
This diminished the overall group 3 condition interaction
(F =3 . 3 1 ,P = 0.085); yet, signiﬁcant regional interactions
were seen in the medial temporal cortex (F = 5.08, P =
0.037) and the insula (F = 4.78, P = 0.042). Also, the voxel-
based mapping analysis revealed a signiﬁcant group dif-
ference in the insulin-induced change in brain glucose
metabolism even with age as a covariate (Tmax =4 . 8 8a t
[36, 248, 210], kE = 34,686 voxels, cluster-level corrected
P , 0.001). This suggests that the phenotype of impaired
glucose tolerance explains the variance in the insulin-
stimulated increase in brain glucose metabolism even when
the effects of age are accounted for.
Cerebral blood ﬂow. In the fasting condition, cerebral
blood ﬂow was similar between patients with impaired
glucose tolerance (n = 6; whole brain: 40.4 mL $ 100 g
21 $
min
21) and healthy subjects (n = 8; whole brain: 41.7 mL $
100 g
21 $ min
21; 23.1%, P = 0.781). The hyperinsulinemic
clamp did not change cerebral blood ﬂow either in patients
with impaired glucose tolerance (whole brain: 22.7%, P =
0.448) or in healthy subjects (whole brain: 24.0%, P = 0.346).
DISCUSSION
We found that insulin stimulates brain glucose metabolism,
but this effect depends on the glucose tolerance of the
subjects: insulin did not increase brain glucose metabolism
in subjects with normal glucose tolerance but signiﬁcantly
increased glucose metabolism in patients with impaired
glucose tolerance. That is, the effect of insulin on brain
glucose metabolism was not maximal in the fasting state in
patients with impaired glucose tolerance, although it was
so in healthy subjects, suggesting that the groups are dif-
ferentially placed on the insulin dose-response curve.
How are these seemingly unexpected results interpreted
in the context of the concept of insulin resistance? With
regard to healthy subjects, our results are consistent with
previous studies that have shown no effects of physiolog-
ical postprandial insulin levels on brain glucose metabo-
lism (10,11). Thus, the effect of insulin on brain glucose
metabolism is already maximal at physiological fasting
insulin levels in healthy subjects, because decreasing in-
sulin levels is able to decrease brain glucose metabolism
(12,13). However, insulin-resistant patients are insensitive
TABLE 1
Demographic and metabolic characteristics of the study groups
Characteristics
Healthy
subjects
Impaired
glucose
tolerance P
n 91 3
Baseline data
Sex (female/male) 4/5 8/5 0.6
Age (years) 38 6 12 49 6 8 0.04
Weight (kg) 75 6 10 112 6 20 ,0.001
BMI (kg/m
2)2 4 6 23 8 6 8 ,0.001
Fat (bioimpedance) (%) 28 6 44 4 6 9 ,0.001
Waist circumference (cm) 85 6 10 119 6 14 ,0.001
Fasting plasma glucose
Ć (mmol/L) 5.3 6 0.5 5.9 6 0.5 0.01
2-h oral glucose tolerance
Ć test (plasma glucose)
Ć (mmol/L) 5.1 6 1.0 8.6 6 1.0 ,0.001
During PET: fasting state
Plasma glucose (mmol/L) 5.4 6 0.4 5.8 6 0.6 0.06
Serum insulin (mU/L) 4 6 31 1 6 4 ,0.001
During PET: hyperinsulinemia
Plasma glucose (mmol/L) 5.1 6 0.3 4.8 6 0.8 0.2
Serum insulin (steady state)
(mU/L) 58 6 57 3 6 19 0.02
Whole-body glucose
uptake (M value)
(mmol $ kg
21 $ min
21)3 0 . 3 6 6.0 11.9 6 4.2 ,0.001
Data are means 6 SD.
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brain responses to insulin in these patients. These ﬁndings
suggest that patients with peripheral insulin resistance
need more insulin than healthy subjects to get the maximal
effect of insulin on brain glucose metabolism. In the fast-
ing condition, we did not ﬁnd lower glucose metabolism in
patients with impaired glucose tolerance, which argues
against simple insulin resistance in the brain. However,
similar glucose metabolism was maintained with higher
plasma insulin levels (Table 1), although the implications
of this observation are unclear, given that decreasing
plasma insulin does not decrease brain glucose metabo-
lism in these patients (12).
Disturbances in brain insulin signaling in patients with
impaired glucose tolerance may occur at multiple levels,
including delivery of insulin in the brain across the blood-
brain barrier, actions of insulin at insulin receptors, and
downstream effects via second-messenger systems (4).
Obese patients have a lower cerebrospinal ﬂuid–to–plasma
insulin ratio (6), which would suggest deﬁcient delivery of
insulin into the brain. However, obese patients also show
decreased catabolic, but not cognitive, responses to in-
tranasal insulin, which bypasses the blood-brain barrier
(7), suggesting that insulin resistance in the brain occurs
at multiple levels. Based on the current results, it may
be speculated that some components along the insulin
pathway in the brain are actually sensitized because of
long-term deprivation of insulin stimulation and show ex-
aggerated responses to high insulin levels in these patients.
For example, if decreased insulin delivery across the
blood-brain barrier and decreased responsiveness of in-
sulin receptors inhibit stimulation of the insulin pathway at
physiological insulin levels, despite compensatory hyper-
insulinemia, we might expect to see increased responses
to insulin when insulin levels are sufﬁciently high to
overcome these deﬁcits upstream in the signaling pathway.
Unfortunately, no evidence for sensitization of any of the
components in this signaling pathway exists in humans,
and this hypothesis remains speculative until further data
emerge.
TABLE 2
Regional brain glucose metabolism values in the fasting and clamp conditions in healthy subjects and in patients with impaired
glucose tolerance
Region
Healthy subjects (n = 9) Impaired glucose tolerance (n = 13)
Group 3 condition
interaction
P
Brain glucose metabolism
(mmol $ 100 g
21 $ min
21) Change
Brain glucose metabolism
(mmol $ 100 g
21 $ min
21) Change
Fast Clamp % P Fast Clamp % P
FRO 15.9 6 1.2 16.4 6 1.5 3.3 0.506 15.8 6 2.1 18.6 6 2.5 18.0 ,0.001 0.009
LTEMP 16.5 6 1.2 17.2 6 1.7 4.2 0.364 16.0 6 1.8 18.8 6 2.2 18.2 ,0.001 0.010
PAR 14.0 6 0.8 14.6 6 1.6 4.5 0.283 14.7 6 1.9 17.2 6 2.5 17.7 ,0.001 0.009
OCC 16.7 6 0.9 17.6 6 2.2 5.5 0.231 17.8 6 2.2 20.7 6 2.9 17.1 ,0.001 0.015
MTEMP 12.8 6 0.6 12.9 6 1.1 1.2 0.778 13.0 6 1.6 15.3 6 1.9 18.3 ,0.001 0.003
INS 17.5 6 1.2 17.7 6 1.7 1.6 0.777 16.3 6 1.9 19.0 6 2.0 17.5 ,0.001 0.003
STR 16.9 6 0.9 17.5 6 1.6 3.8 0.340 16.2 6 2.3 19.2 6 2.2 20.2 ,0.001 0.013
CER 10.6 6 1.2 10.9 6 1.5 3.4 0.529 10.7 6 1.9 12.2 6 2.0 16.5 0.035 0.150
THA 16.4 6 1.6 17.1 6 2.3 5.0 0.327 16.2 6 2.9 19.5 6 2.6 22.9 ,0.001 0.020
P values are from paired samples t tests except for the last column, where P values are from the group 3 condition interaction in repeated-
measures ANOVA. P values denoting statistical signiﬁcance (P , 0.05) appear in boldface. CER, cerebellum; FRO, frontal cortex; INS, insula;
LTEMP, lateral temporal cortex; MTEMP, mesial temporal cortex; OCC, occipital cortex; PAR, parietal cortex; STR, striatum; THA, thalamus.
FIG. 1. The percentage of the insulin-stimulated increase in brain glucose metabolism is higher in subjects with impaired glucose tolerance. The
increase in brain glucose metabolism in patients with impaired glucose tolerance was similar across brain regions, ranging from 16% in the cer-
ebellum to 23% in the thalamus. Error bars represent the SEM.
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roparameter CMRglu and cannot therefore distinguish
between increased glucose transport across the blood-
brain barrier and increased brain hexokinase activity in
patients with impaired glucose tolerance. Similarly, we
cannot distinguish whether the effects of insulin on brain
glucose metabolism are direct by stimulation of glucose
metabolism, or indirect by stimulation of neuronal activity
via neurotransmitter activity. Because our PET measure-
ments with [
15O]H2O showed no effects of insulin on ce-
rebral blood ﬂow, we conclude that insulin does not
increase brain delivery of glucose simply by increased
cerebral blood ﬂow. Previous studies have found decreased
baseline cerebral blood ﬂow in patients with type 1 (22) and
type 2 (23) diabetes, likely representing microvascular
damage from chronic hyperglycemia. We did not ﬁnd such
alterations in patients with impaired glucose tolerance,
suggesting that microvascular damage may be minimal
in this prediabetic state, insofar as biologically meaningful
deﬁcits are detected by [
15O]H2O PET.
The highest insulin-stimulated increase in glucose me-
tabolism was seen in the posterior insula, a region that
monitors bodily states and is implicated in reward func-
tions (24). A recent study (25) found increased functional
responses to gastric distention in obese subjects in the
posterior insula. Thus, the posterior insula may be one of
the regions where insulin reduces feeding behavior in
humans.
In conclusion, we used [
18F]FDG PET to show that in-
sulin does not stimulate brain glucose metabolism at phys-
iological postprandial levels in healthy subjects but does so
in patients with impaired glucose tolerance. These results
suggest that insulin regulation of brain glucose metabolism
is disturbed in metabolic syndrome.
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